Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hosp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...

MADISON, Wis., Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024. BTIG-hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management, please contact your BTIG representative with interest. About AccurayAccuray is committed to expanding the powerful potential of radiation therapy to ...

Accuray Incorporated (ARAY) reported loss per share of 10 cents for the second quarter of fiscal 2024, wider than the year-ago period’s loss of 2 cents per share. The metric was also wider than the Zacks Consensus Estimate of a loss of 7 cents per share.Revenues in DetailAccuray registered revenues of $107.2 million in the second quarter of fiscal 2024, down 6.6% year over year. The figure, however, topped the Zacks Consensus Estimate by 0.1%.The overall top-line growth was dampened by lower Products revenu ...

Accuray Incorporated (NASDAQ:ARAY) Q2 2024 Earnings Conference Call January 31, 2024 4:30 PM ET Company Participants Jesse Chew - Senior Vice President, Chief Legal Officer Suzanne Winter - Chief Executive Officer Ali Pervaiz - Senior Vice President and Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Second Quarter Fiscal 2024 Financial Results. All participants will be in listen-only mode. [ ...

Accuray (ARAY) reported $107.24 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.6%. EPS of -$0.10 for the same period compares to -$0.02 a year ago.The reported revenue represents a surprise of +0.12% over the Zacks Consensus Estimate of $107.11 million. With the consensus EPS estimate being -$0.07, the EPS surprise was -42.86%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Group 1 - The upcoming report from Accuray (ARAY) is expected to show a quarterly loss of $0.07 per share, a decline of 250% compared to the previous year [1] - Analysts forecast revenues of $107.11 million, indicating a decrease of 6.7% year over year [1] - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, reflecting analysts' reassessment of their projections [1] Group 2 - Analysts expect 'Net revenue- Services' to be $50.70 million, a year-over-year change of -1.6% [2] - 'Net revenue- Products' is predicted to reach $56.41 million, showing a change of -10.8% from the year-ago quarter [2] - The average estimate for 'Order Backlog' is $462.45 million, down from $515.24 million a year ago [2] - Analysts suggest 'Net Orders' will likely be $61.16 million, compared to $40.87 million in the previous year [2] Group 3 - 'Gross Orders' are expected to be $81.74 million, an increase from $79.04 million reported in the same quarter last year [3] - Accuray shares have returned +1.1% over the past month, compared to the Zacks S&P 500 composite's +3.4% change [3] - With a Zacks Rank 3 (Hold), ARAY is anticipated to mirror overall market performance in the near future [3]

Accuray Incorporated (ARAY) recently announced that the Providence Swedish Radiosurgery Center in Seattle, WA, is purchasing the latest generation CyberKnife S7 System. This purchase will be the hospital's second CyberKnife radiation delivery device purchase.With the purchase of the latest CyberKnife, the center is expecting to enhance its cancer treatment capabilities. The robotic nature of the device will also enable precision and accuracy, making it a perfect option for treating neurologic problems. This ...

Core Insights - Accuray Incorporated announced the purchase of the CyberKnife® S7™ System by the Providence Swedish Radiosurgery Center, enhancing cancer treatment capabilities in Seattle, Washington [1][2] - The new system is designed for precision and speed, enabling faster delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, thus improving patient access to effective treatment options [1][2] Company Overview - Accuray is focused on expanding the potential of radiation therapy to improve patient lives, offering innovative solutions for complex cases while simplifying treatment for more common cases [5] - The company emphasizes continuous innovation in radiation therapy for oncology and neuro-radiosurgery, partnering with clinicians to enhance patient care [5] Product Details - The CyberKnife S7 System is a non-invasive radiation therapy device that utilizes artificial intelligence to track and adapt to tumor or patient movement, delivering radiation with sub-millimeter precision in as little as 15 minutes [2][3] - The system represents a significant advancement in operational efficiency without compromising treatment accuracy, aligning with the goal of improving patient outcomes [2][3] Partnership and Impact - The partnership between Accuray and the Providence Swedish Radiosurgery Center has been ongoing for over a decade, with the center previously using the first CyberKnife System [2][3] - The center has contributed to the field of radiation medicine through significant clinical trials and ongoing research, demonstrating a commitment to advancing treatment methodologies [3]

MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on January 31, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one we ...